SynthesisFrontiers in oncology2026
Elevated thymidine kinase 1 expression at baseline predicts poor prognosis in breast cancer patients.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thymidine kinase 1 (TK1), a key enzyme in DNA biosynthesis, has been shown to correlate with breast cancer prognosis and treatment response in dynamic monitoring settings. However, the clinical relevance of baseline TK1 levels remains controversial due to inconsistent evidence across studies. To address this issue, we conducted the first systematic meta-analysis of available studies to investigate the potential association between baseline TK1 levels and prognostic outcomes in breast cancer patients. Methods: A comprehensive computerized literature search was conducted across major Chinese and English databases to identify studies investigating the association between TK1 expression and breast cancer prognosis. Baseline TK1 expression levels and corresponding patient survival data were systematically extracted for meta-analysis. Results: The meta-analysis evaluating the association between baseline TK1 expression levels and progression-free survival (PFS) in breast cancer included 2,887 patients from 11 studies. Significant heterogeneity was observed across the included studies ( Conclusion: Breast cancer patients presenting with high baseline TK1 expression are associated with significantly worse prognostic outcomes. Collectively, these findings support the clinical potential of TK1 assessment for prognostic risk stratification and treatment guidance, which merits further verification in large-scale, multicenter clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.